Esta web utiliza cookies técnicas, de personalización y de análisis, propias y de terceros, para anónimamente facilitarle la navegación y analizar estadísticas del uso de la web. Obtener más información
Resultados de búsqueda
-
Sanofi-Aventis's Tender Offer for Genzyme
Eades, Kenneth M.; Matos, Pedro; Aleyev, Dmitriy; Xu, ChongCaso DARDEN-F-1716-EFinanzasIn October 2010, Henri Termeer, the chairman and CEO of Genzyme, received a letter from the CEO of Sanofi-Aventis announcing its intention to commence a tender offer for Genzyme. Termeer thought the offer undervalued Genzyme, given the number of promising new drugs in the company’s pipeline and the success of its current drug portfolio. The case focuses on the strategic and financial considerations of a large corporate acquisition. To estimate Ge...Desde 8,20 €
-
The Sanofi-Aventis Acquisition of Genzyme: Contingent Value Rights
Matos, Pedro; Aleyev, Dmitriy; Xu, ChongCaso DARDEN-F-1715-EFinanzasThis case is designed for MBA students in M&A or derivatives courses. In January 2011, Sanofi-Aventis was finalizing its offer terms for acquiring Genzyme. The M&A valuation disputes were about the market potential of alemtuzumab, a drug in Genzyme’s pipeline, and how quickly Genzyme could resolve some of its manufacturing issues. To bridge the gap in their estimates, advisers had suggested an up-front cash payment and a contingent value right (C...Desde 8,20 €
-
Genzyme and Relational Investors: Science and Business Collide? - Teaching Note
Eades, Kenneth M.; Matos, PedroNota del Instructor DARDEN-F-1660TN-EFinanzasTeaching note for product F-1660Desde 0,00 €
-
Genzyme and Relational Investors: Science and Business Collide?
Eades, Kenneth M.; Matos, Pedro; Green, RickCaso DARDEN-F-1660-EFinanzasThe chairman and CEO of the Genzyme Corporation, one of the country’s top five biotechnology firms, has received a phone call requesting a meeting with the cofounder and principal of a large activist investment fund that now has a 2.6% stake in his company. Before meeting with him, the CEO is aware that he needs a strategy for dealing with this “activist” investor with a track record of forcing out CEOs.Desde 8,20 €
-
F-Secure Corporation: Software as a Service (SaaS) in the Security Solutions Market, Teaching Note
Austin, Robert D.; Applegate, Lynda M.; Lyytinen, Kalle; Penttinen, Esko; Saarinen, TimoNota del Instructor HBS-809151-EMarketingTeaching Note for [809099].Desde 0,00 €
-
F-Secure Corporation: Software as a Service (SaaS) in the Security Solutions Market
Applegate, Lynda M.; Austin, Robert D.; Lyytinen, Kalle; Penttinen, Esko; Saarinen, TimoCaso HBS-809099-ETecnologías de la informaciónDescribes the development of a business model based on "software as a service" (SaaS) for security solution distributed through Internet Service Providers (ISPs). F-Secure disruptively entered a mature business with dominant players by executing an innovative new service model. The case describes the challenges involved in developing and executing the new service model, and offers students opportunities to discuss the evolving challenges the comp...Desde 8,20 €
-
IBM's Decade of Transformation: Uniting Vision and Values (Spanish Version)
Applegate, Lynda M.; Austin, Robert D.; Heckscher, Charles C.; Michael, Boniface; Collins, ElizabethCaso HBS-811S18Liderazgo y Dirección de personasComplementa el caso (A). Un resumen no está disponible para este producto.Desde 8,20 €